Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

Inclusion criteria

• Patient is between 18 and 60, inclusive.
• Patient is HBV DNA positive with DNA levels at screening >= 3 x 1,000,000 copies/mL.
• Patient is documented to be HBsAg positive for > 6 months and HBeAg positive.
• Patient has AST and ALT levels which are >= 1 times and <= 10 times the upper limit of normal (x ULN).
• Patient has bilirubin levels <= 1.5 x ULN or bilirubin levels > 1.5 x ULN with diagnosis of Gilbert's disease and conjugated bilirubin within normal limits.
• Women of childbearing age must have a negative urine (b-HCG) pregnancy test before start of trial treatment.
• Patient is able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion criteria

• Patient is currently receiving antiviral, immunomodulatory or corticosteroid therapy.
• Patients previously treated with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection.
• Previous treatment with interferon must have ended at least 6 months prior to the screening visit.
• Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
• Patient is co-infected with HCV or HIV.
• Patient has evidence of decompensated cirrhosis or hepatocellular carcinoma (alpha fetoprotein).
• Patient is pregnant or breast-feeding.
• Patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases. For males, condoms should be used. Females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal, or using at least a medically acceptable barrier method of contraception (i.e., IUD, barrier methods with spermicide or abstinence).
• Patient has a clinically relevant history of abuse of alcohol or drugs.
• Patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
• Subjects who are currently participating in another investigational study or has been taking any investigational drug within the last 4 weeks prior to Screening Visit.
• Subjects who are taking any traditional Chinese medication, or has been taking any traditional Chinese medication within the last 2 weeks prior to Screening Visit.
• Any criteria, which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol.